Zhitong Finance App News, Weilizhibo-B (09887) issued an announcement. At the 2026 Annual Meeting of the European Society of Medical Oncology (2026 ESMO), the key registered phase IIB clinical study for the single-agent treatment of advanced extrapulmonary neuroendocrine cancer (“EP-NEC), a key registered phase IIB clinical study for the treatment of advanced extrapulmonary neuroendocrine cancer (“EP-NEC)” has been selected for the latest breakthrough abstract (LBA) and qualified for oral report presentation. It marks the innovative nature of the research being developed independently. and significant clinical value, its The findings are expected to change existing clinical practice and reshape the standard treatment pattern for advanced EP NEC. It is worth noting that in 2026, ESMO's three studies were selected for oral presentation, and the number selected was among the highest among Chinese pharmaceutical companies.
Details of the studies selected for the LBA are set out below.
Study title: Opatisumimab (LBL-024) monotherapy for advanced extrapulmonary neuroendocrine cancer (EP-NEC) previously treated with second-line treatment or above: Key registration phase IIb study results of a novel PD-L1x4-1bb bispecific antibody
Presentation format: Preferred oral presentation; Main researcher: Professor Shen Lin, Peking University Cancer Hospital; Speaker: Director Lu Ming, Peking University Cancer Hospital; Presentation time: October 26, 10:15 a.m. to 10:25 a.m. local time.
The key phase IIb study was selected by ESMO to evaluate the efficacy and safety of Velisin® monotherapy in advanced EP-NEC patients who have previously received at least second-line systemic treatment. The study data provided core support for the company to submit a new drug marketing application (NDA) to the relevant regulatory authorities.
At ESMO in 2026, the company was eligible to present three preferred oral reports, including: (i) a key registered phase IIb study for advanced EP-NEC with Velisign® (selected for LBA); (ii) a phase IB/II study of first-line treatment of EP-Nec with Velisign® combined chemotherapy; and (iii) a phase I study of LBL-034 treating recurrent or refractory multiple myeloma (RRMM).
Preferred oral reports are one of ESMO's highest standard oral report categories. Only high-quality Yuanchuang research materials are awarded, representing the international oncology community's recognition of research innovation, data quality and clinical value. The company simultaneously selected three studies for ESMO for oral reports in 2026, which is not only a breakthrough in single-point research, but also a comprehensive affirmation of the company's innovative ability, clinical development system and multi-tumor layout, fully demonstrating the company's ability to continuously produce high-quality clinical research and participate in international academic competition.
In addition, the company also successfully selected four high-quality studies for the conference poster, covering clinical research of Villison® in biliary tract cancer (BTC), mechanistic research in microsatellite-stabilized colorectal cancer, and multiple integrated analyses. From clinical exploration of solid tumors to systematic review of research data, the company's detailed and diversified research and development team was presented in a comprehensive and multi-faceted manner.